November 1, 2019 - BioPharma Dive
Amgen will pay Chinese oncology specialist BeiGene $2.7 billion for a 21% stake in a wide-ranging collaboration that will see BeiGene commercialize three marketed cancer drugs and up to 20 in development in China. BeiGene has a significant marketing presence in China thanks to its assumption of in-country rights for three Celgene drugs.
Xgeva, Blincyto and Kyprolis will be the initial focus of the deal, with the two companies equally sharing profits and losses on sales of the drugs in China. Rights to two of the products will revert to Amgen after five and seven years.
October 30, 2019 - Fierce Biotech
Prescription digital therapeutic developer Pear Therapeutics is expanding its app-based platform to conditions outside of the brain and mental health through a gastrointestinal disease-focused collaboration with Ironwood Pharmaceuticals.
October 29, 2019 - BioPharma Dive
Pfizer's new heart drug nearly quadrupled Wall Street sales expectations in its first full quarter of sales in the U.S., quickly carving out a spot in a therapeutic market that features rival therapies from Alnylam Pharmaceuticals and Ionis Pharmaceuticals.
Vyndaqel posted $156 million in global sales across the three months of July, August and September, with $79 million coming from the U.S. market. Wall Street's consensus estimate was $21 million in U.S. sales, according to Evercore ISI analyst Umer Raffat, who also pointed out a faster-than-expected rate of diagnosis for the rare disease treated by Vyndaqel.
October 28, 2019 - Fierce Pharma
Advent International said Zentiva would make a great platform on which to build a generics powerhouse when it bought the European generics unit from Sanofi last year for $2.2 billion. Since then, the private equity investor has quickly piled on more acquisitions and manufacturing sites as it builds a significant generics operation.
Zentiva now has a
to buy Labormed, the Romania-based Central and Eastern European business, of Alvogen, which includes a 71,000-square-foot manufacturing facility in Bucharest. Zentiva is also taking on Labormed’s 1,000 employees. Terms were not disclosed.
Labormed manufactures more than 200 generic and over-the-counter products, including brands like Lactacyd and Persen, and sells into in Russia, Bulgaria, Hungary, Poland and Balkan markets, in addition to Romania, the companies said.